Immunomic Therapeutics Inc. Senior Director of Corporate Development Sia Anagnostou will participate in ISPE’s first Women in Pharma Event in Gaithersburg, MD.
Panel participants include:
- Sia Anagnostou, Senior Director of Corporate Development, Immunomic Therapeutics
- Shiva Frietsch, Sr. Vice President HR, RegenxBIO
- Marcella Goodnight, Director, Global Technical Operations, AstraZeneca Biologics
- Dr. Katherine Sacksteder, PhD, COO, Benevir Biopharm Inc.
- Dr. Judy Steveley, Program Director Bioprocessing Technology, Assistant Professor, Frederick Community College
- Moderator: Shannah Falcone, Senior Associate / Director Strategic Accounts, CRB
Who: Immunomic Therapeutics, Inc. Senior Director of Corporate Development Sia Anagnostou
What: ISPE’s Women in Pharma Panel Discussion
When: Tuesday, March 27, 4-7:40 p.m. EDT
Where: Montgomery College, Pinkney Innovation Complex: Science and Technology, 20200 Observation Drive, Gaithersburg, MD
About LAMP-Vax
ITI’s investigational LAMP-Vax platform is thought to work by encoding the Lysosomal Associated Membrane Protein, an endogenous protein in humans. In this way, ITI’s vaccines (DNA or RNA) have the potential to utilize the body’s natural biochemistry to develop a broad immune response including antibody production, cytokine release and critical immunological memory. This approach could put LAMP-Vax technology at the crossroads of immunotherapies in a number of illnesses, including cancer, allergy and infectious diseases. LAMP is currently being employed in Phase II clinical trials as a cancer immunotherapy. ITI is also collaborating with academic centers and biotechnology companies to study the use of LAMP in cancer types of high mortality, including cases where there are limited treatment options like glioblastoma and acute myeloid leukemia. ITI believes that these early clinical studies may provide a proof of concept for LAMP-Vax therapy in cancer, and if successful, set the stage for future studies, including combinations in these tumor types and others. Preclinical data is currently being developed to explore whether LAMP nucleic acid constructs may amplify and activate the immune response in highly immunogenic tumor types and be used to create immune responses to tumor types that otherwise do not provoke an immune response.
